(REASON) Double-blind, Randomized Phase II Study to Evaluate the Safety and Efficacy of Acetyl-l-carnitine in the Prevention of Sagopilone-induced Peripheral Neuropathy.

Trial Profile

(REASON) Double-blind, Randomized Phase II Study to Evaluate the Safety and Efficacy of Acetyl-l-carnitine in the Prevention of Sagopilone-induced Peripheral Neuropathy.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Feb 2017

At a glance

  • Drugs Levacecarnine (Primary) ; Prednisolone; Prednisone; Sagopilone
  • Indications Peripheral neuropathies
  • Focus Therapeutic Use
  • Acronyms REASON
  • Sponsors Bayer
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 08 Feb 2017 New source identified and integrated (ISRCTN75009754; ISRCTN: Current Controlled Trials).
    • 25 Sep 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top